FATE analyst estimates
Fate Therapeutics (FATE) analyst ratings, the average price target and its range, and every firm's latest call.
- 4 firms rate FATE: 3 buy, 1 hold, 0 sell.
- The average price target is $6.17 from None analysts, from $3.50 to $8.00.
FATE analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 14, 2026 | Wells Fargo | Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo | $3.50 |
| Aug 14, 2026 | Piper Sandler | Fate Therapeutics price target raised to $8 from $6 at Piper Sandler | $8.00 |
| Jun 8, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE) | $7.00 |
| May 19, 2026 | Jefferies | Fate Therapeutics assumed with a Buy at Jefferies | $4.00 |
| Mar 6, 2025 | Stifel Nicolaus | Fate Therapeutics price target lowered to $3 from $5 at Stifel | $3.00 |
| Nov 13, 2024 | BMO Capital | Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital | $5.00 |
| Aug 14, 2024 | Stifel Nicolaus | Fate Therapeutics (FATE) PT Lowered to $5 at Stifel | $5.00 |
| Jun 17, 2024 | Piper Sandler | Piper Sandler Upgrades Fate Therapeutics (FATE) to Overweight | $6.00 |
| May 16, 2024 | H.C. Wainwright | Fate Therapeutics (FATE) PT Lowered to $5 at H.C. Wainwright | $5.00 |
| May 10, 2024 | Canaccord Genuity | Fate Therapeutics price target lowered to $9 from $11 at Canaccord | $9.00 |
| May 10, 2024 | BMO Capital | Fate Therapeutics (FATE) PT Lowered to $6 at BMO Capital | $6.00 |
| May 10, 2024 | Piper Sandler | Fate Therapeutics (FATE) PT Lowered to $4 at Piper Sandler | $4.00 |
| Jan 9, 2023 | Goldman Sachs | Goldman Sachs Maintains Sell on Fate Therapeutics, Lowers Price Target to $4 | $4.00 |
| Jan 6, 2023 | Piper Sandler | Piper Sandler Downgrades Fate Therapeutics to Neutral, Lowers Price Target to $12 | $12.00 |
| Jan 6, 2023 | Morgan Stanley | Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8 | $8.00 |